US FDA pauses Gilead trials testing experimental HIV pill combination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
FDA clinical hold a 'blow to Gilead Sciences (GILD) HIV pipeline - Oppenheimer
June 10, 2025 11:14 AM EDTOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD) but said the clinical hold is a 'blow' to the company's HIV pipeline.
The analyst commented, "This morning, Gilead announced that the FDA had put ongoing GS-4182+GS-1720... More
